<DOC>
	<DOC>NCT02734849</DOC>
	<brief_summary>This is a phase 2 study to evaluate multiple doses of AK001 across 2 active doses. Pharmacodynamic activity will also be evaluated.</brief_summary>
	<brief_title>Study to Evaluate Multiple Doses in Patients With Nasal Polyposis</brief_title>
	<detailed_description>AK001 is a monoclonal antibody which may be useful in the treatment of patients with moderate to severe nasal polyposis</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Nasal Polyps</mesh_term>
	<criteria>TPS of ≥5 for both nostrils with presence on endoscopy of nasal polyps of grade ≥2 in each nostril according to the polyp grading scale History of sinusitis symptoms SNOT22 ≥30 No clinically significant Screening 12lead ECG, vital sign, hematology, chemistry, or urinalysis findings Use of systemic corticosteroids within 6 weeks of screening Chronic use of antibiotic therapy within 3 months prior to Screening Nasal surgery (including polypectomy) within 6 months prior to Screening Use of investigational drugs or participation in another clinical trial within 30 days prior to Screening or 5 half‑lives, whichever is longer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>